C4 Therapeutics, Inc. Proceeds from Sale and Maturity of Marketable Securities
C4 Therapeutics, Inc. (CCCC) reported Proceeds from Sale and Maturity of Marketable Securities of $113.08 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities · last filed 2026-08-11
- C4 Therapeutics, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2026-06-30 was $56.05M, a 7.79% decline year-over-year.
- C4 Therapeutics, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2026-03-31 was $57.03M, a 4.13% increase year-over-year.
- C4 Therapeutics, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2025-12-31 was $52.35M, a 3.86% decline year-over-year.
- C4 Therapeutics, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2025-09-30 was $51.18M, a 25.52% decline year-over-year.
- C4 Therapeutics, Inc. proceeds from sale and maturity of marketable securities for fiscal 2025 was $219.08M, a 6.07% decline from fiscal 2024.
- C4 Therapeutics, Inc. proceeds from sale and maturity of marketable securities for fiscal 2024 was $233.23M, a 19.56% decline from fiscal 2023.
- C4 Therapeutics, Inc. proceeds from sale and maturity of marketable securities for fiscal 2023 was $289.95M, a 2.30% increase from fiscal 2022.
- C4 Therapeutics, Inc. proceeds from sale and maturity of marketable securities for fiscal 2022 was $283.44M, a 18.94% decline from fiscal 2021.
| Period end | Proceeds from Sale and Maturity of Marketable Securities 3 month | Proceeds from Sale and Maturity of Marketable Securities 6 month | Proceeds from Sale and Maturity of Marketable Securities 9 month | Proceeds from Sale and Maturity of Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $56.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $113.08M 10-Q · filed 2026-08-11 | $165.43M derived: sum of 3 quarters · filed 2026-08-11 | $216.61M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $57.03M 10-Q · filed 2026-05-12 | $109.38M derived: sum of 2 quarters · filed 2026-05-12 | $160.56M derived: sum of 3 quarters · filed 2026-05-12 | $221.34M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $52.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $103.53M derived: sum of 2 quarters · filed 2026-02-26 | $164.31M derived: sum of 3 quarters · filed 2026-08-11 | $219.08M 10-K · filed 2026-02-26 |
| 2025-09-30 | $51.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $111.97M derived: sum of 2 quarters · filed 2026-08-11 | $166.73M 10-Q · filed 2025-11-06 | $221.18M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $60.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $115.55M 10-Q · filed 2026-08-11 | $170.00M derived: sum of 3 quarters · filed 2026-08-11 | $238.72M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $54.77M 10-Q · filed 2026-05-12 | $109.22M derived: sum of 2 quarters · filed 2026-05-12 | $177.93M derived: sum of 3 quarters · filed 2026-05-12 | $233.64M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $54.45M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $123.16M derived: sum of 2 quarters · filed 2026-02-26 | $178.88M derived: sum of 3 quarters · filed 2026-02-26 | $233.23M 10-K · filed 2026-02-26 |
| 2024-09-30 | $68.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $124.43M derived: sum of 2 quarters · filed 2025-11-06 | $178.78M 10-Q · filed 2025-11-06 | $248.76M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $55.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $110.07M 10-Q · filed 2025-08-07 | $180.05M derived: sum of 3 quarters · filed 2025-08-07 | $270.31M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $54.35M 10-Q · filed 2025-05-07 | $124.33M derived: sum of 2 quarters · filed 2025-05-07 | $214.60M derived: sum of 3 quarters · filed 2025-05-07 | $278.75M derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | $69.98M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $160.25M derived: sum of 2 quarters · filed 2025-02-27 | $224.40M derived: sum of 3 quarters · filed 2025-02-27 | $289.95M 10-K · filed 2025-02-27 |
| 2023-09-30 | $90.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $154.42M derived: sum of 2 quarters · filed 2024-10-31 | $219.97M 10-Q · filed 2024-10-31 | $287.04M derived: sum of 4 quarters · filed 2024-10-31 |
| 2023-06-30 | $64.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $129.71M 10-Q · filed 2024-08-01 | $196.77M derived: sum of 3 quarters · filed 2024-08-01 | $275.10M derived: sum of 4 quarters · filed 2024-08-01 |
| 2023-03-31 | $65.56M 10-Q · filed 2024-05-08 | $132.62M derived: sum of 2 quarters · filed 2024-05-08 | $210.94M derived: sum of 3 quarters · filed 2024-05-08 | $276.62M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $67.06M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $145.39M derived: sum of 2 quarters · filed 2024-02-22 | $211.06M derived: sum of 3 quarters · filed 2024-02-22 | $283.44M 10-K · filed 2024-02-22 |
| 2022-09-30 | $78.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | $144.00M derived: sum of 2 quarters · filed 2023-11-01 | $216.38M 10-Q · filed 2023-11-01 | $302.49M derived: sum of 4 quarters · filed 2023-11-01 |
| 2022-06-30 | $65.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $138.06M 10-Q · filed 2023-08-08 | $224.17M derived: sum of 3 quarters · filed 2023-08-08 | $278.24M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $72.39M 10-Q · filed 2023-05-04 | $158.50M derived: sum of 2 quarters · filed 2023-05-04 | $212.57M derived: sum of 3 quarters · filed 2023-05-04 | $307.07M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $86.11M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $140.19M derived: sum of 2 quarters · filed 2023-02-23 | $234.69M derived: sum of 3 quarters · filed 2023-02-23 | $349.68M 10-K · filed 2023-02-23 |
| 2021-09-30 | $54.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $148.57M derived: sum of 2 quarters · filed 2022-11-03 | $263.57M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $94.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $209.49M 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | $114.99M 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | $104.00M 10-K · filed 2022-02-24 | |||
| 2019-12-31 | $78.67M 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |